(78 days)
Not Found
No
The description focuses on the electrical stimulation parameters and the device's physical components and operation, with no mention of AI or ML capabilities for data analysis, treatment personalization, or other functions.
Yes
The device is intended for the acute treatment of pain associated with episodic cluster headache and migraine headache, which falls under the definition of a therapeutic device designed to treat a medical condition.
No
This device is intended for treatment (noninvasive vagus nerve stimulation for pain associated with cluster headache and migraine), not for diagnosis.
No
The device description explicitly details hardware components such as an outer plastic case, battery, signal generating and amplifying electronics, LED, horn, LCD display screen, and stainless steel skin contact surfaces. It also describes the physical mechanism of action (producing an electric signal transmitted through the skin).
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "acute treatment of pain associated with episodic cluster headache and migraine headache in adult patients" by providing "noninvasive vagus nerve stimulation (nVNS) on the side of the neck." This describes a therapeutic intervention applied directly to the patient's body.
- Device Description: The device description details a hand-held portable device that produces an electric signal transmitted through the skin to the vagus nerve. This is a physical stimulation device, not a device that analyzes biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (like blood, urine, tissue, etc.) or providing information about a patient's health status based on such analysis. IVDs are designed to be used in vitro (outside the body) to examine specimens.
Therefore, the gammaCore-S Non-invasive Vagus Nerve Stimulator is a therapeutic medical device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The gammaCore-S Non-invasive Vagus Nerve Stimulator is intended to provide noninvasive vagus nerve stimulation (nVNS) on the side of the neck. The gammaCore -S device is indicated for the acute treatment of pain associated with episodic cluster headache and migraine headache in adult patients.
Product codes
PKR, QAK
Device Description
The gammaCore-S device (Catalog # 10009-40601 gammaCore-S, 31 day, 300 treatment device) is a hand-held portable device consisting of an outer plastic case, a battery, signal generating and amplifying electronics, LED and horn (indicate device status), and a pair of stainless steel skin contact surfaces (referred to as the "stimulation surfaces"). The device operating status is visible on a LCD display screen. Caps are provided to cover the stimulation surfaces when the device is not in use. Conductive electrode gel is provided for use with the device.
The gammaCore-S device produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. The waveform of the electric pulses is approximately a sine wave with a peak voltage limited to 24 Volts when placed on the skin and a maximum output current of 60mA. The signal is transmitted through the skin of the neck to the vagus nerve. The device allows up to 30 seconds for the operator to position and adjust the stimulation intensity, treatment is intended to be applied for 90 seconds (the treatment automatically stops 120 seconds after the device is powered on). Each device allows for multiple treatments (up to 300 2-minute treatments).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
side of the neck
Indicated Patient Age Range
adult patients
Intended User / Care Setting
Prescription Use (Part 21 CFR 801 Subpart D)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical data demonstrating the safety and effectiveness of the gammaCore-S for the treatment of migraine headache was collected from a multicenter, randomized, double-blind, parallel-group, sham-controlled study took place across 10 expert headache centers in Italy from January 11, 2016 through March 31, 2017. The study was designed to compare nVNS to sham treatment and included three 4-week periods. During the study, nVNS was superior to sham in aborting the first treated attack at 30 and 60 minutes but not at 120 minutes (primary end point). A repeated-measures test validated the primary end point, indicating the superiority of nVNS over sham through 120 minutes. Significant benefits of nVNS were also shown across several clinically relevant secondary end points including mild or no pain at 120 minutes, changes in pain intensity from baseline to 60 and 120 minutes, and ≥50% responder (pain free and mild/pain free) rates at 120 minutes. Consistent with previous studies of nVNS for the treatment of primary headache, nVNS was safe and well tolerated.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
gammaCore-S K171306
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.5892 External vagal nerve stimulator for headache.
(a)
Identification. An external vagal nerve stimulator for headache is a prescription device used to apply an electrical current to a patient's vagus nerve through electrodes placed on the skin for the treatment of headache.(b)
Classification. Class II (special controls). The special controls for this device are:(1) The technical parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and 10,000 ohm loads), pulse duration, frequency, net charge (µC) per pulse, maximum phase charge at 500 ohms, maximum current density (mA/cm
2 , r.m.s.), maximum average current (mA), maximum average power density (W/cm2 ), and the type of impedance monitoring system shall be fully characterized through non-clinical performance testing.(2) Software verification, validation, and hazard analysis shall be performed.
(3) Biocompatibility evaluation of the patient-contacting components of the device shall be performed.
(4) The device shall be tested for electrical, thermal, and mechanical safety, and for electromagnetic compatibility (EMC).
(5) The labeling must include:
(i) Instructions for proper use of the device, including placement of the device on the patient; and
(ii) Instructions on care and cleaning of the device.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
January 23, 2018
electroCore, LLC Mike Romaniw VP, Quality Assurance & Regulatory Affairs 150 Allen Road. Suite 201 Basking Ridge, New Jersey 07920
Re: K173442
Trade/Device Name: gammaCore-S Regulation Number: 21 CFR 882.8592 Regulation Name: External Vagus Nerve Stimulator for Headache Regulatory Class: Class II Product Code: PKR, QAK Dated: November 3, 2017 Received: November 6, 2017
Dear Mike Romaniw:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
William J. Heetderks -A 2018.01.23 11:04:12 -05'00'
for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K173442
Device Name gammaCore-S
Indications for Use (Describe)
The gammaCore-S Non-invasive Vagus Nerve Stimulator is intended to provide noninvasive vagus nerve stimulation (nVNS) on the side of the neck. The gammaCore -S device is indicated for the acute treatment of pain associated with episodic cluster headache and migraine headache in adult patients.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart G) |
| X | Prescription Use (Part 21 CFR 801 Subpart D)
|__| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
The following information is provided as required by 21 CFR § 807.87 for the electroCore gammaCore-S 510(k) premarket notification. In response to the Safe Medical Devices Act of 1990, the following is a summary of the information upon which the substantial equivalence determination is based.
| Applicant: | electroCore® LLC |
|---|---|
| 150 Allen Road, Suite 201 | |
| Basking Ridge, New Jersey 07920 | |
| Ph: 973-290-0097 | |
| Fax: 973-290-9171 |
Establishment Registration Number: 3009060963
| Contact: | Mike Romaniw |
|---|---|
| VP, Quality Assurance & Regulatory Affairs | |
| Office: 973-355-6702 | |
| Fax: 973-290-9171 | |
| Mike.Romaniw@electroCoreLLC.com | |
| Alternate Contact: | Eric J. Liebler |
| VP, Scientific, Medical and Clinical Affairs | |
| Mobile: 908-938-9780 | |
| Eric.Liebler@electroCoreLLC.com | |
| Alternate Contact: | Marie Marlow |
| Chief Executive Officer | |
| M Squared Associates, Inc. | |
| Office: 855-776-0638 x201 | |
| Fax: 703-562-9797 | |
| MMarlow@MSquaredAssociates.com | |
| Alternate Contact: | Janice M. Hogan, Esq. |
| Partner | |
| Hogan Lovells US LLP | |
| Direct: 267-675-4611 | |
| Janice.Hogan@HoganLovells.com |
4
| Date of Submission: | 03 November 2017 |
|---|---|
| Proprietary Name: | gammaCore-S® |
| Common Name: | External vagal nerve stimulator for headache s |
| Classification Status: | Class II |
| Product Codes: | PKR, QAK |
| Predicate Device: | gammaCore-S K171306 |
Indication for Use: The gammaCore-S Non-invasive Vagus Nerve Stimulator is intended to provide noninvasive vagus nerve stimulation (nVNS) on the side of the neck. The gammaCore-S device is indicated for the acute treatment of pain associated with episodic cluster headache and migraine headache in adult patients.
gammaCore-S Device Description: The gammaCore-S device (Catalog # 10009-40601 gammaCore-S, 31 day, 300 treatment device) is a hand-held portable device consisting of an outer plastic case, a battery, signal generating and amplifying electronics, LED and horn (indicate device status), and a pair of stainless steel skin contact surfaces (referred to as the "stimulation surfaces"). The device operating status is visible on a LCD display screen. Caps are provided to cover the stimulation surfaces when the device is not in use. Conductive electrode gel is provided for use with the device.
The gammaCore-S device produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. The waveform of the electric pulses is approximately a sine wave with a peak voltage limited to 24 Volts when placed on the skin and a maximum output current of 60mA. The signal is transmitted through the skin of the neck to the vagus nerve. The device allows up to 30 seconds for the operator to position and adjust the stimulation intensity, treatment is intended to be applied for 90 seconds (the treatment automatically stops 120 seconds after the device is powered on). Each device allows for multiple treatments (up to 300 2-minute treatments).
There is no change to the gammaCore-S device as cleared in K171306. The purpose of this submission is for an expanded indication for treatment of pain associated with migraine in adult patients.
Summary of Technological Characteristics: There is no change to the technological characteristics in the gammaCore-S (K171306) for this expanded indication.
5
Summary of Non-Clinical Testing:
There is no change to the technological characteristics in the gammaCore-S (K171306) for this expanded indication; no additional non-clinical or performance testing is required.
Summary of Clinical Data:
Clinical data demonstrating the safety and effectiveness of the gammaCore-S for the treatment of migraine headache was collected from a multicenter, randomized, double-blind, parallel-group, sham-controlled study took place across 10 expert headache centers in Italy from January 11, 2016 through March 31, 2017. The study was designed to compare nVNS to sham treatment and included three 4-week periods. During the study, nVNS was superior to sham in aborting the first treated attack at 30 and 60 minutes but not at 120 minutes (primary end point). A repeatedmeasures test validated the primary end point, indicating the superiority of nVNS over sham through 120 minutes. Significant benefits of nVNS were also shown across several clinically relevant secondary end points including mild or no pain at 120 minutes, changes in pain intensity from baseline to 60 and 120 minutes, and ≥50% responder (pain free and mild/pain free) rates at 120 minutes. Consistent with previous studies of nVNS for the treatment of primary headache, nVNS was safe and well tolerated.
Substantial Equivalence Discussion:
The gammaCore-S device technology is identical to the device technology used in the gammaCore-S indicated for the acute treatment of pain associated with episodic cluster headache in adult patients. There have been no changes in the technological characteristics nor intended use of the gammaCore-S device for acute treatment of pain associated with migraine headache in adult patients. Due to differences in the characteristics of these two primary headache conditions, there is a difference in the treatment instructions for the device associated with episodic cluster headache versus migraine headache. For both indications, use of more than 8 gammaCore-S treatments per day (for a total of 24 stimulations per day) has not been evaluated and is listed as a precaution in the labeling.
Summary:
The following table summarizes the comparison of the substantial equivalence of the subject device to that of the predicate device.
Table 1. Substantial Equivalence Comparison Table
6
| gammaCore-S | gammaCore-S | Substantial Equivalence | |
|---|---|---|---|
| 510(k) number | Subject device | K171306 | |
| Indication for Use | gammaCore-S is indicated for | ||
| the acute treatment of pain | |||
| associated with episodic cluster | |||
| and migraine headache in adult | |||
| patients. | gammaCore-S is indicated for | ||
| the acute treatment of pain | |||
| associated with episodic cluster | |||
| headaches in adult patients. | Clinical data supports the | ||
| expanded indication | |||
| statement. Questions of | |||
| safety or effectiveness | |||
| have been addressed in | |||
| supporting data. | |||
| Intended Use | gammaCore-S is a device that | ||
| provides non-invasive Vagus | |||
| Nerve Stimulation (nVNS) | |||
| when applied to the side of the | |||
| neck. This is a mild electrical | |||
| stimulation of the vagus nerve, | |||
| which runs through the neck | |||
| and carries information to the | |||
| central nervous system. Each | |||
| stimulation with gammaCore | |||
| lasts two minutes. The patient | |||
| controls the stimulation | |||
| strength. | gammaCore-S is a device that | ||
| provides non-invasive Vagus | |||
| Nerve Stimulation (nVNS) | |||
| when applied to the side of the | |||
| neck. This is a mild electrical | |||
| stimulation of the vagus nerve, | |||
| which runs through the neck | |||
| and carries information to the | |||
| central nervous system. Each | |||
| stimulation with gammaCore | |||
| lasts two minutes. The patient | |||
| controls the stimulation | |||
| strength. | No change in intended use | ||
| Rx vs. OTC | Prescription use only | Prescription use only | No change. |
| Treatment | |||
| Recommendation | Acute treatment of migraine: | ||
| 120 second stimulation cycle, 2 | |||
| bi-lateral stimulations, up to 3 | |||
| times a day. | Acute treatment of eCH: | ||
| 120 second stimulation cycle, | |||
| 3 consecutive stimulations up | |||
| to 8 times/day. | Change in treatment | ||
| protocol to reflect | |||
| different form of primary | |||
| headache. Supported by | |||
| clinical data in Section 20 | |||
| of this submission. | |||
| Patient- contacting | |||
| Materials | SS, ABS-PC, Signagel | ||
| electrode gel | SS, ABS-PC, Signagel | ||
| electrode gel | No change in materials | ||
| Electrical | |||
| Classification | UL 60601-1 Class III Type BF | ||
| Applied Part | UL 60601-1 Class III Type BF | ||
| Applied Part | No change in | ||
| classification | |||
| Waveform / | |||
| frequency | Sinusoidal wave, Symmetrical | ||
| biphasic | |||
| 5000 Hz pulses at a rate of 25 | |||
| Hz | Sinusoidal wave, Symmetrical | ||
| biphasic | |||
| 5000 Hz pulses at a rate of 25 | |||
| Hz | No change in waveform | ||
| or frequency | |||
| Maximum output | 30V (peak), 60 mA(peak) | 30V (peak), 60 mA(peak) | No change in outputs |
| Load impedance | 450-550 Ohms | 450-550 Ohms | No change in impedance |
| Power Supply | 3V Lithium battery | 3V Lithium battery | No change in power |
| supply voltage | |||
| Service Life | 1.5 years after manufacture date | 1.5 years after manufacture date | No change in service life |
| Device Circuitry | |||
| Controls | Increase (+) and decrease (-) | ||
| push buttons | Increase (+) and decrease (-) | ||
| push buttons | No change in circuitry or | ||
| controls | |||
| gammaCore-S | gammaCore-S | Substantial Equivalence | |
| Output regulation | Device software and push | ||
| buttons | Device software and push | ||
| buttons | |||
| Device status | |||
| display | LCD screen | LCD screen | |
| Electrical | |||
| Interface Port | For programming software and | ||
| troubleshooting only; enclosure | |||
| must be opened for access to | |||
| the interface port | For programming software and | ||
| troubleshooting only; enclosure | |||
| must be opened for access to | |||
| the interface port | |||
| Optical Port | |||
| Infrared | |||
| Connection | Service port intended for | ||
| manufacturer's access only; | |||
| receiver only, cannot transmit; | |||
| shows battery voltage, allows | |||
| resetting of days and doses. | Service port intended for | ||
| manufacturer's access only; | |||
| receiver only, cannot transmit; | |||
| shows battery voltage, allows | |||
| resetting of days and doses. | |||
| Audible Signals / Alarms | |||
| Start up | Yes | Yes | No change in available |
| alarm signals. | |||
| Session complete | Yes | Yes | |
| Errors / depleted | |||
| battery | Yes | Yes | |
| No doses left | Yes | Yes | |
| Expired / no days | |||
| left | Yes | Yes | |
| Visual Indicators / Display | |||
| Start up | |||
| (powered on) | Light on | Light on | |
| Unit ready | |||
| (powered on) | Light on / LCD amplitude "0" | Light on / LCD amplitude "0" | |
| Session complete | Light off / LCD days, doses | ||
| remaining and last amplitude | Light off / LCD days, doses | ||
| remaining and last amplitude | |||
| Errors / depleted | |||
| battery | LCD "Err" / Flashing Light | LCD "Err" / Flashing Light | No change to |
| display/message. | |||
| No doses left | Flashing light / LCD # doses | ||
| remaining | Flashing light / LCD # doses | ||
| remaining | |||
| Expired / no days | |||
| left | Flashing light / LCD days | ||
| remaining | Flashing light / LCD days | ||
| remaining | |||
| Low battery | No light / LCD Display "Lo" | No light / LCD Display "Lo" |
7
Conclusion:
There have been no changes in the technological characteristics nor intended use of the gammaCore-S device for acute treatment of pain associated with migraine headache in adult patients. The addition of migraine headache to the indications for use does not raise new or different questions of safety or effectiveness compared to that of the predicate device. Therefore,
8
K173442
the presented information demonstrates that the subject device is substantially equivalent to the predicate device.